ReproCyc PRRS EU
ATC code
Species
Pigs
Indications
For active immunisation of breeding females from farms affected with European (genotype 1) Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) to reduce the duration of viraemia, the proportion of viraemic gilts/sows and viral loads in blood after exposure to PRRSV as shown under experimental conditions.
Onset of immunity: 4 weeks
Duration of immunity: 17 weeks
Vaccination of breeding females according to the recommended schedule described in section 4.9 reduces the negative reproductive disorders associated with PRRSV.
Under experimental challenge conditions a reduction in transplacental virus transmission after challenge was additionally demonstrated. In piglets from vaccinated sows, a reduction in the negative impact of PRRS virus infection (mortality, clinical signs and weight gain) was also demonstrated during the first 20 days of life.
Dose to be administered and administration route
Dosage and method of administration:
Single intramuscular injection of one dose (2 ml), irrespective of body weight. For reconstitution, transfer the entire content of the solvent vial to the vial containing the lyophilisate and reconstitute the lyophilisate as follows: 10 doses in 20 ml, 50 doses in 100 ml and 100 doses in 200 ml of the solvent.
Ensure that the lyophilisate is completely reconstituted before use.
Visual appearance after reconstitution: clear, colourless suspension.
Avoid introduction of contamination during use.
Use sterile equipment.
Avoid multiple broaching, for example by using automatic injectors.
Regime of vaccination:
|
Gilts: |
for protection against PRRSV during pregnancy vaccination is recommended before integration into the sow herd between 2 and 5 weeks prior to breeding. Gilts can then be subjected to the same vaccination programme as the sow herd. |
|
Sows: |
it is recommended to vaccinate pregnant and non-pregnant sows every 3 to 4 months. |
Mixing with ReproCyc ParvoFLEX:
The full content of one vial of ReproCyc ParvoFLEX should be used to reconstitute the lyophilisate of one vial of ReproCyc PRRS EU. ReproCyc ParvoFLEX hereby replaces the solvent of ReproCyc PRRS EU.
Ensure that the lyophilisate is completely reconstituted before use. Administer a single dose (2 ml) of the mixture intramuscularly.
The following corresponding presentations (doses) can be mixed:
|
ReproCyc PRRS EU (lyophilisate) |
ReproCyc ParvoFLEX |
|
10 doses |
10 doses (20 ml) |
|
50 doses |
50 doses (100 ml) |
|
100 doses |
100 doses (200 ml) |
The package leaflet of ReproCyc ParvoFLEX should also be consulted before the administration of the mixed product.
Adverse reactions
A transient increase in body temperature (up to 2°C above the physiological range) commonly occurs up to 5 days post-vaccination. Temperatures return to the normal range without additional treatment, 1 to 4 days after the maximum temperature increase is observed.
Reduced appetite may be observed commonly after vaccination.
Very minimal swelling or redness of the skin at the injection site may be observed commonly. These reactions (up to 10.5 cm but typically < 2 cm in size) are transient and subside within a short time (maximum of 5 days but typically less than 2 days) without treatment.
Recumbency and accelerated breathing can be observed uncommonly on the day of vaccination. These signs disappear spontaneously without any treatment.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 08327/4301 |
| EAN | 5012917012101 |
